Clinical trial · Observational
Functional MRI in Predicting Response to Chemotherapy
Superadded Value of Functional MRI Techniques in Evaluation of Malignant Breast Cancers Following Clips Guided Neoadjuvant Chemotherapeutic Series
NCT03969524CI-TRIAL-00049158MRIunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
• Address the accuracy of functional MRI techniques to predict response to neoadjuvant chemotherapy given to local advanced breast cancer patients with correlation with pathology thus allowing early chemotherapy regimen modification to increase number of patients achieving pathological complete response or save patients from toxic effects of ineffective chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- correlations coefficient between functional techniques of MRI breast and histology
- timeFrame
- 3 years
- description
- by appropriate statistical test
- measure
- changes in the different functional technique's parameters according to the type of response.
- timeFrame
- 3 years
- description
- by appropriate statistical test
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patient in different age groups with local advanced breast cancer who are eligible for neoadjuvant chemotherapy and breast conservative surgery and in need for clip placement for tumor localization Exclusion Criteria: * Patient with breast cancer who are not eligible for NAC (pregnant patients, multicentric breast cancer, metastatic breast cancer). * Patients who have received any prior chemotherapy, radiation therapy or tamoxifen therapy for their current breast cancer * Patients with any general contraindication to MRI as presence of any paramagnetic substance as pacemakers, or those with claustrophobia.
References
Publications (2)
- BACKGROUNDRieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002 Jul;12(7):1711-9. doi: 10.1007/s00330-001-1233-x. Epub 2002 Feb 14. PMID 12111062
- BACKGROUNDTaourel P, Pages E, Millet I, Bourgier C, Rouanet P, Jacot W, Crochet P, Azria D. Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy. Crit Rev Oncol Hematol. 2018 Dec;132:51-65. doi: 10.1016/j.critrevonc.2018.09.012. Epub 2018 Sep 25. PMID 30447927